MS clinical trials

Researchers call for more pragmatic clinical trials in MS

Few multiple sclerosis (MS) clinical trials have used a so-called pragmatic design, which evaluates the effectiveness of interventions in real-life routine practice, a study has found. Because such trials are better able to emulate conditions in real-world clinical practice and provide solid and more actionable evidence to inform treatment…

GlobeStar adds another partner for Project Amethyst clinical trial

Advanced Innovative Partners (AIP) has agreed to assist GlobeStar Therapeutics Corporation and SMI Healthcare in designing and running clinical trials to evaluate Project Amethyst, a patented triple combination of U.S.-approved medications aiming to prevent neurodegeneration due to multiple sclerosis (MS). This definitive agreement follows a…

Brain volume loss helps in judging DMT efficacy in RRMS: Review

The rate of brain atrophy, or volume loss, may help in determining whether disease-modifying therapies (DMTs) are slowing disability progression in people with relapsing-remitting multiple sclerosis (RRMS), a review of data from 12 published studies found. The analysis, ā€œBrain Atrophy as an Outcome of Disease-Modifying Therapy for…

Is Aubagio still ethical to use as comparator in MS trials?

Noting that Aubagio (teriflunomide) continues to have “a robust impact on disability progression” in multiple sclerosis (MS) despite being eclipsed by newer MS treatments in trials, an international team of researchers are now arguing that it is, in fact, still ethical to use the older therapy as a…

GlobeStar, AIP team up to design clinical trials for Project Amethyst

GlobeStar TherapeuticsĀ (GSTC) is teaming up with Advanced Innovative Partners (AIP) to design and implement clinical trials of Project Amethyst, an investigational therapy for multiple sclerosisĀ (MS) that aims to reduce neurodegeneration ā€” when nerve cells in the body lose function and ultimately die. The new memorandum of understanding (MOU)…